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Kinesin-Like Protein-6 and Coronary Disease November 2, 2010:1552–63Objectives We sought to replicate the association between the kinesin-like protein 6 (KIF6) Trp719Arg polymorphism
(rs20455), and clinical coronary artery disease (CAD).
Background Recent prospective studies suggest that carriers of the 719Arg allele in KIF6 are at increased risk of clinical CAD
compared with noncarriers.
Methods The KIF6 Trp719Arg polymorphism (rs20455) was genotyped in 19 case-control studies of nonfatal CAD either
as part of a genome-wide association study or in a formal attempt to replicate the initial positive reports.
Results A total of 17,000 cases and 39,369 controls of European descent as well as a modest number of South Asians,
African Americans, Hispanics, East Asians, and admixed cases and controls were successfully genotyped. None
of the 19 studies demonstrated an increased risk of CAD in carriers of the 719Arg allele compared with noncar-
riers. Regression analyses and fixed-effects meta-analyses ruled out with high degree of confidence an increase
of 2% in the risk of CAD among European 719Arg carriers. We also observed no increase in the risk of CAD
among 719Arg carriers in the subset of Europeans with early-onset disease (younger than 50 years of age for
men and younger than 60 years of age for women) compared with similarly aged controls as well as all non-
European subgroups.
Conclusions The KIF6 Trp719Arg polymorphism was not associated with the risk of clinical CAD in this large replication
study. (J Am Coll Cardiol 2010;56:1552–63) © 2010 by the American College of Cardiology Foundationp
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necent prospective observational studies suggest an associ-
tion between the Trp719Arg single nucleotide polymor-
hism (SNP) in kinesin-like protein 6 (rs20455) and the
evelopment of clinical coronary artery disease (CAD)
1–5). Carriers of the 719Arg alleles were found to have a
odest increase in the risk in the Atherosclerosis
See page 1564
isk in Communities study (ARIC) (hazard ratio [HR]
ssuming log additive model: 1.11; 95% confidence interval
CI]: 1.02 to 1.21, p  0.02) (1), the CHS (Cardiovascular
ealth Study) (HR assuming log dominant model: 1.29;
5% CI: 1.1 to 1.52, p  0.005) (5), and the WHS
Women’s Health Study) (HR assuming log dominant
odel: 1.24; 95% CI: 1.04 to 1.46, p  0.01) (4).
olecular Medicine, University of Helsinki, Helsinki, Finland; 66Department of
linical Sciences, Hypertension and Cardiovascular Diseases, University Hospital
almö, Lund University, Malmö, Sweden; 67Department of Medicine, McGill
niversity, Montreal, Quebec, Canada; 68National, Heart, Lung, and Blood Institute
nd its Framingham Heart Study, Framingham, Massachusetts; and the 69Mid-
merica Heart Institute and University of Missouri-Kansas City, Kansas City,
issouri. The collection of clinical and sociodemographic data in the Dortmund
ealth Study was supported by the German Migraine & Headache Society (DMKG)
nd by unrestricted grants of equal share from AstraZeneca, Berlin Chemie, Boots
ealthcare, GlaxoSmithKline, McNeil Pharma (former Woelm Pharma), MSD
harp & Dohme and Pfizer to the University of Muenster. Recruitment of the
edstar sample was supported by a research grant from GlaxoSmithKline and
enotyping of the PennCATH and Medstar samples was supported by GlaxoSmith-
line. Drs. Ho´lm, Thorleifsson, Thorsteinsdottir, and Stefansson are employees of
eCODE genetics, a for-profit company that develops SNP based diagnostic tests for
arious diseases including coronary artery disease. Drs. Mooser, Walker, and
aterworth are employees of GlaxoSmithKline. Dr. Knouff was employed at
laxoSmithKline at the time data were generated for this manuscript. Dr. Altshuler
as received research funds from Pfizer. Dr. Kathiresan has received consulting fees
rom Pfizer, Alnylam, Merck, Daiichi Sankyo, and Novartis. Dr. Reilly has received
esearch funds from Merck. Dr. Shah has received research funds from Medtronic. All
ther authors have reported that they have no relationships to disclose.c
Manuscript received November 28, 2009; revised manuscript received June 14,
010; accepted June 22, 2010.An increase in the risk of CAD was also observed in the
lacebo arm of 2 statin trials: the WOSCOPS (West of
cotland Coronary Prevention Study) (odds ratio [OR] for
ncident CAD events assuming log dominant model: 1.55;
5% CI: 1.14 to 2.09, p  0.005) and the CARE (Choles-
erol and Recurrent Events) trial (HR for recurrent myo-
ardial infarction [MI] assuming log dominant model: 1.50;
5% CI: 1.05 to 2.15, p  0.03) (3). Curiously, carriers of
he 719Arg allele were not at increased risk of CAD or
ecurrent MI in the pravastatin arms of these 2 trials.
urthermore, in the PROVE IT–TIMI 22 (Pravastatin or
torvastatin Evaluation and Infection Therapy–Thrombolysis
n Myocardial Infarction 22) trial, carriers in the pravastatin
rm were also not at increased risk of CAD, whereas carriers
n the atorvastatin arm had a decreased risk compared with
oncarriers (adjusted HR: 0.65; 95% CI: 0.48 to 0.88; p 
.005) (2). The discrepant results between the 2 arms of
hese 3 statin trials were deemed a consequence of a
ifferential effect of genotype on the benefit derived from
he use of statins with carriers benefiting to a larger degree
rom statin therapy than noncarriers (2,3). Because carriers
andomized to the more potent statin were actually at
ecreased risk compared with noncarriers in the PROVE
T–TIMI 22 trial, it was hypothesized that the degree of
ncremental benefit from statin use among carriers was a
unction of the intensity of lipid-lowering therapy (2).
The results of these initial studies have been used to
ustify the development of a KIF6 Trp719Arg variant
harmacogenomic test (Statincheck) (6). This test is cur-
ently being marketed to health care professionals as an aid
o identifying subjects at high risk of incident or recurrent
AD events who stand to gain the most from the use of
tatins (6,7). However, in recent genome-wide association
tudies for CAD and/or MI, SNPs at the KIF6 locus were
ot among the associations reaching genomewide signifi-
ance (8–12). Furthermore, in the ongoing Ottawa Heart
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November 2, 2010:1552–63 Kinesin-Like Protein-6 and Coronary Diseaseenomics Study, no association was found between the
IF6 Trp719Arg SNP and angiographically defined CAD
n a subset of 1,540 cases and 1,455 controls (13). These
iscrepant results demand examination of this association in
dditional populations to substantiate the use of the KIF6
est in the management of subjects at risk of clinical CAD.
In this paper, we report association analyses for the KIF6
rp719Arg SNP in 19 case-control studies of CAD that
ave recently genotyped this SNP using various genotyping
latforms either as part of a genome-wide association study
r in a formal attempt to replicate the initial positive reports
1–5).
ethods
tudy populations. We included subjects participating in
9 different case-control studies of CAD conducted around
he world: the ADVANCE (Atherosclerotic Disease, VAs-
ular functioN, and genetiC Epidemiology) study (14) of
orthern California; the AMI Gene Study/Dortmund
ealth (15) in Germany; the CATHGEN Research Project
16) in North Carolina; the deCODE CAD study (10) in
celand; the National FINRISK study (17) in Finland; the
ibling GeneSTAR (Genetic Study of Atherosclerosis Risk)
18) in Maryland; the GerMIFS I and Ger-MIFS II
German Myocardial Infarction Family) studies (8) in
ermany; the HARPS (Heart Attack Risk in Puget Sound)
19) study in Washington state; the international INTER-
EART study (20,21) coordinated by the Population
ealth Research Institute of McMaster University in Ham-
lton, Ontario, Canada; the IFS (Irish Family Study) (22) in
reland; the MDC (Malmo Diet and Cancer) study in
weden, the MEDSTAR (Medstar/Washington Hospital
enter) (10) study in Washington, DC; the MGH PCAD
Massachusetts General Hospital Premature CAD) study
24) in Boston, Massachusetts; the MAHI (Mid-America
eart Institute) study (25,26) in Kansas City, Missouri; the
ennCATH (University of Pennsylvania Medical Center
ardiac catheterization cohort) study (10) in Philadelphia,
ennsylvania; the REGICOR (Registre Gironı’ del Cor)
27) study in Girona, Spain; the VHS (Verona Heart Study)
28) in Verona, Italy; and the WTCCC CAD (Wellcome
rust Case Control Consortium study of Coronary Artery
isease) (11) in the United Kingdom. All participants gave
ritten informed consent, and local ethics committees
pproved all studies.
Investigators from several of these 19 studies are members
f consortia with a primary interest of identifying novel
enetic determinants of CAD through the use of genome-
ide association study technology. The consortia include
he PennCATH/MedStar consortium composed of the
ennCATH and MedStar studies, the Myocardial Infarc-
ion Genetics consortium (MIGen) (12) composed of the
ARPS, REGICOR, MGH PCAD, FINRISK, and
DC studies; the Cardiogenics consortium (8) composedf the WTCCC, GerMIFS I, GerMIFS II studies; and phe CARDIoGRAM (Coro-
ary ARtery Disease Genome-
ide Replication And Meta-
nalysis) consortium composed
f the ADVANCE study, the
eCODE study, and the Penn/
edStar, MIGen, and CAR-
IOGENICS consortia.
Each study used standard cri-
eria to identify cases with MI
stablished by international orga-
izations during the 1990s or
ore recently. Although some of these studies restricted
heir enrollment of cases to subjects with at least 1 MI,
thers included cases diagnosed with clinically significant
oronary atherosclerosis without MI. Elevation of cardiac
arkers (creatine kinase-MB or troponin) and symptoms
nd/or electrocardiography suggestive of cardiac ischemia
ere typical criteria used to identify MI cases. Non-MI
ases included subjects with angina and confirmatory test
esults for ischemia, unstable angina based on symptoms,
nd electrocardiographic changes without elevation of car-
iac enzymes, and revascularization procedures that may
ave occurred in the presence or absence of symptoms. For
he current analyses, both CAD cases with and without a
iagnosis of MI were considered to emulate the outcome
sed in the majority of the prospective studies published to
ate (1–5).
Most of the studies either only enrolled subjects of
uropean descent or restricted their genotyping efforts to
uropeans. However, in addition to Europeans, the
DVANCE study genotyped a modest number of Afri-
an Americans, Hispanics, East Asians, and admixed
ndividuals; the CATHGEN and GeneSTAR studies
enotyped a modest number of African Americans; and
he INTERHEART study genotyped a large number of
outh Asians.
More details on the design of each study including the
recise criteria used by each of the 19 studies to ascertain
ases and controls can be found in the Online Appendix and
elated references.
enotyping. The Trp719Arg polymorphism in kinesin-
ike protein 6 (rs20455) was directly genotyped in all
tudies, and no imputation of the genotype was necessary.
or the GerMIFS I and WTCCC CAD studies, the
enotyping data were extracted from the Affymetrix 500k
rray (29). For the deCODE, ADVANCE, and Gene-
TAR studies, the genotyping data were extracted from the
llumina Infinium HumanHap317/370, 550, and 1M chip
rrays, respectively (29). For the GerMIFS II, FINRISK,
ARPS, MDC, MGH PCAD, PennCATH, Medstar,
nd REGICOR studies, the genotyping data were extracted
rom the Affymetrix 6.0 array (29). For the AMI Gene, IFS,
NTERHEART, and MAHI studies, the SNP was geno-
yped using the iPLEX MassARRAY platform (Sequenom)
Abbreviations
and Acronyms
CAD  coronary artery
disease
CI  confidence interval
HR  hazard ratio
MI  myocardial infarction
OR  odds ratio
SNP  single nucleotide
polymorphismlatform (29). Finally, for CATHGEN and VHS, the SNP
Study Design of Case-Control Studies Included in the Meta-Analysis of the Trp719Arg Polymorphism (rs20455)in Kinesin-Like Protein-6 and Basic Demographic C aracteristics of Par icipants Stratified by Case-Control StatusTable 1 Study D sig of C e-Contr Stu es Included in the Meta-Analysi of the Trp719Arg P lym rphism (rs20455)in Kinesin-Like Protein-6 and Basic Demographic Characteristics of Participants Stratified by Case-Control Status
Study n* Country of Study Ascertainment Scheme
Qualifying
Event Age (yrs)/Sex Criterion
Age, yrs
(Mean  SD)
%
Female
% Non-
European
ADVANCE
Cases 505 U.S. Population- based CAD Men 45 or women 55 45.4 6.5 61.5 45.7
Controls 514 U.S. Population- based — — 45.6 5.7 61.3 39.5
AMI Gene
Cases 793 Germany Hospital-based MI Men 65 52.2 8.2 0.0 0.0
Controls 1,121 Germany Hospital-based — — 52.6 13.7 53.1 0.0
CATHGEN
Cases 1,575 U.S. Hospital-based MI 18 men or women 61.9 11.9 28.9 17.6
Controls 970 U.S. Hospital-based — 18 men or women 56.6 11.8 52.4 24.7
deCODE
Cases 4,313 Iceland Population- based CAD No age criterion 68.9 12.1 30.8 0.0
Controls 24,952 Iceland Population- based — — 49.2 21.7 63.2 0.0
FINRISK
Cases 167 Finland Drawn from population-based cohort MI Men 50 or women 60 47.1 6.2 33.5 0.0
Controls 172 Finland Nested case-cohort — — 47.1 6.0 31.4 0.0
GeneSTAR
Cases 378 U.S. Hospital-based CAD Men and women 60 46.9 7.0 26.2 24.6
Controls 2,652 U.S. Unaffected siblings of cases — — 47.2 13.1 58.2 40.5
GerMIFS I
Cases 722 Germany Hospital-based MI Men 60 or women 65 50.2 7.9 32.5 0.0
Controls 1,643 Germany Population-based — — 62.5 10.1 50.5 0.0
GerMIFS II
Cases 1,126 Germany Hospital-based MI Men 60 or women 65 51.3 7.6 20.3 0.0
Controls 1,277 Germany Hospital-based — — 51.2 11.9 47.9 0.0
HARPS
Cases 505 U.S. Community-based MI Men 50 or women 60 46.0 6.9 51.1 0.0
Controls 559 U.S. Community-based — — 45.2 7.3 55.5 0.0
INTERHEART (Europeans)
Cases 789 Several† Hospital-based MI No age criterion 61.6 12.3 29.0 0.0
Controls 859 Several† Hospital- and community-based — — 61.2 12.2 30.7 0.0
INTERHEART (South Asians)
Cases 1,092 Several‡ Hospital-based MI No age criterion 51.4 10.8 10.1 100.0
Controls 1,187 Several‡ Hospital- and community-based — — 49.8 11.0 9.1 100.0
IFS
Cases 482 Northern Ireland Hospital-based MI Men 55 or women 60 46.0 6.3 20.1 0.0
Controls 622 Northern Ireland Older siblings of cases — — 55.2 8.0 55.2 0.0
MDC
Cases 86 Sweden Drawn from population-based cohort MI Men 50 or women 60 48.5 4.4 41.9 0.0
Controls 99 Sweden Nested case-cohort — — 48.7 4.6 42.4 0.0
Continued on next page
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ContinuedTable 1 Continued
Study n* Country of Study Ascertainment Scheme
Qualifying
Event Age (yrs)/Sex Criterion
Age, yrs
(Mean  SD)
%
Female
% Non-
European
MedStar
Cases 875 U.S. Hospital-based CAD Men and women 65 48.9 6.4 18.2 0.0
Controls 447 U.S. Hospital-based — Men and women 45 59.8 8.9 48.8 0.0
MGH PCAD
Cases 204 U.S. Hospital-based MI Men 50 or women 60 47.0 6.1 29.9 0.0
Controls 260 U.S. Hospital-based — — 53.8 11.1 33.5 0.0
MAHI
Cases 807 U.S. Hospital-based MI No age criterion 61.5 12.7 32.1 0.0
Controls 637 U.S. Outpatients — — 60.7 12.4 39.0 0.0
PennCATH
Cases 933 U.S. Hospital-based CAD Men and women 66 52.7 7.6 24.3 0.0
Controls 468 U.S. Hospital- based — Men and women 45 61.7 9.6 51.7 0.0
REGICOR
Cases 312 Spain Hospital-based MI Men 50 or women 60 45.9 5.8 20.2 0.0
Controls 317 Spain Drawn from community-based cohort — — 46.0 5.6 21.5 0.0
VHS
Cases 1,106 Italy Hospital-based CAD No age criterion 61.4 10.0 20.4 0.0
Controls 383 Italy Hospital-based — — 58.0 12.3 35.0 0.0
WTCCC CAD
Cases 1,922 U.K. Community-based CAD Men and women 66 49.3 7.9 20.2 0.0
Controls 2,933 U.K. Community-based — — 44.7 9.3 49.2 0.0
*Total number of subjects with successful genotyping of rs20455. †Predominantly from Europe. ‡Predominantly from India, Pakistan, Bangladesh, and Sri Lanka.
ADVANCE Atherosclerotic Disease, VAscular functioN, and genetiC Epidemiology; AMI Gene AMI Gene Study/Dortmund Health; CAD coronary artery disease; CATHGEN CATHGEN Research Project; deCODE deCODE genetics CAD study; FINRISK National Finrisk
study; GeneSTAR  Genetic Study of Atherosclerosis Risk; GerMIFS I and GerMIFS II  German Myocardial Infarction Family studies I and II; HARPS  Heart Attack Risk in Puget Sound; IFS  Irish Family Study; INTERHEART  international INTERHEART study coordinated
by Population Health Research Institute of McMaster University; MAHI  Mid-America Heart Institute; MDC  Malmo Diet and Cancer; MedStar  Washington Hospital Center/MedStar angiographic CAD study; MGH PCAD  Massachusetts General Hospital of Premature
CAD study; MImyocardial infarction; PennCATH University of Pennsylvania Medical center angiographic CAD study; REGICOR Registre Gironı’ del Cor study; U.K. United Kingdom; U.S. United States; VHS Verona Heart Study; WTCCC CADWellcome Trust Case
Control Consortium study of CAD.
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Kinesin-Like Protein-6 and Coronary Disease November 2, 2010:1552–63as genotyped using the Centaurus platform (29). All
enotype data generated from the various platforms passed
xtensive quality control measures including tests of Hardy-
einberg equilibrium (p  0.001 in controls).
linical measures. The age at onset of clinical CAD (for
ases) and sex for cases and controls were documented in all
tudies. The presence of other traditional risk factors was
ocumented in most but not all studies. In the deCODE
tudy, risk factor data other than age, sex, and body mass
ndex were not collected. Furthermore, the presence of other
raditional risk factors was defined in various ways, and the
iming of enrollment of cases hampered the accurate mea-
urement of these risk factors in some studies. For example,
everal studies enrolled cases weeks to months (and some-
imes years) after their initial CAD event, making it difficult
o reliably discern whether certain medications being taken
y a participant at the time of enrollment were prescribed to
reat risk factors present before their first ever clinical
anifestation of CAD versus for secondary prevention
easons or to treat CAD symptoms (e.g., beta-blockers,
alcium channel blockers, angiotensin-converting enzyme
nhibitors, and statins). No attempt was made to standardize
isk factor definitions across all studies.
tatistical analysis. We first calculated the crude ORs and
5% CIs based on the 2  2 table of KIF6 Trp719Arg
llele-by-trait counts for each case-control study. In case-
ontrol studies with 1 race/ethnic group, we calculated an
R for each race/ethnic group. We then compared the
istribution of the raw genotype counts in each case-control
tratum with Armitage’s trend test (30). Next, we calculated
Rs and 95% CIs adjusted for age at onset of CAD and sex
sing standard unconditional logistic regression. Because of
he difficulties in ascertaining risk factors other than age and
ex, we did not adjust ORs for any additional CAD risk
actors. Log additive and dominant ORs were calculated
ecause both modes of inheritance were reported to date.
he 719Trp allele served as the reference allele given that
he 719Arg allele was identified as the high-risk allele in
revious publications. Analyses were repeated after exclud-
ng case subjects with an age at onset of CAD of 50 years
nd older for men and 60 years and older for women.
ontrols for this subgroup analysis were also restricted to
hose in the same sex-specific age range as cases at the time
f enrollment. The GeneSTAR family study analyses were
erformed using generalized linear latent and mixed models
ith the logistic link and family membership as the random
ffect to account for family structure, whereas the Irish
amily Study used likelihood-based association statistics
ncorporated in the UNPHASED software package (31) to
ccount for family structure. In the latter family study, only
he crude ORs for the additive model using all subjects
ould be calculated.
Last, we combined crude and adjusted ORs, 95% CIs,
nd p values using a Mantel-Haenszel model in which the
roups were allowed to have different population frequen-
ies for genotypes but were assumed to have common telative risks (32). We weighed the results from each study
y the standard error of the effect derived from the p value
f the OR (see the Online Appendix for details). Using this
eta-analytic approach, we calculated the overall combined
Rs, 95% CIs, and p values separately for all case control
tudies of Europeans and all case-control studies of African
mericans. The meta-analyses were repeated for the sub-
roup of cases in each study with early-onset disease and
heir respective controls. For each meta-analysis, we also
erformed 2 standard heterogeneity tests (Cochran’s Q and
iggins’ I2) to assess the appropriateness of a fixed-effects
odel over a random-effects model (33).
From previous work, we know that 1 of the 2 admixed
ace/ethnic strata in the ADVANCE study, the admixed
on-Hispanics, has significant differences in the degree
f admixture between cases and controls (14). Specifi-
ally, cases in this stratum are, on average, significantly
ore European (and less African American) than con-
rols. Therefore, we included a covariate in the multivar-
ate regression model indicating the proportion of white
ncestry for each individual estimated by the program
TRUCTURE (34,35) in this stratum. The other admixed
tratum in the ADVANCE study, the admixed Hispanics,
id not show differences in degree of admixture between
ases and controls. Therefore, no additional covariates were
dded to the regression model for this stratum.
Some Icelandic affected individuals and controls are
elated, both within and between groups, causing the
hi-square test statistic to have a mean 1 and a median
arger than 0.6752. The inflation factor, lambda (), was
stimated at 1.21 using a method of genomic control (36) by
alculating the average of the observed chi-square statistics
or the genome-wide SNP set, which accounts for related-
ess and for potential population stratification. The 95%
Is and p values presented for deCODE are based on
djusting the chi-square statistics by dividing it by this
nflation factor. The inflation factor was also found to be high
n the GerMIFS I study ( 1.27); therefore, p values and
5% CIs for this study were also adjusted in the same manner.
or all other studies with genome-wide data, a genomic
ontrol correction was not applied to the data because the
nflation factor was found to be very low (  1.05).
We performed sensitivity analyses by repeating all anal-
ses after excluding non-MI cases in the subset of case-
ontrol studies that included both MI and non-MI cases of
AD. These sensitivity analyses were performed only in
uropeans.
esults
able 1 summarizes the ascertainment scheme and the
nclusion criteria for phenotype, age, sex, and race stratified
y study and case-control status. The distribution and
requency of all traditional risk factors of CAD stratified by
tudy and case-control status can be found in Table 1S in
he Online Appendix. Of the 19 case-control studies, 12
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November 2, 2010:1552–63 Kinesin-Like Protein-6 and Coronary Diseasenrolled only cases with MI and 14 also restricted enroll-
ent or genotyping to early-onset disease (when consider-
ng the traditional age cutoffs of 65 years and younger for
omen and 55 years and younger for men at the time of first
nset of disease). However, the largest study (deCODE)
nrolled both MI and non-MI cases of CAD and included
AD cases with any age at onset. The proportion of cases
hat were women patients varied from study to study and
as influenced by the ascertainment scheme and matching
either one to one or frequency matching). The overall
eighted average age at onset of CAD was 55.7 years.
Table 2 summarizes the genotype counts stratified by
tudy, case control status, and race/ethnic group as well as
he adjusted OR, 95% CI, and p values for the association
etween KIF6 rs20455 SNP and CAD. Crude ORs were
ot materially different from their respective ORs adjusted
or age and sex. Therefore, only ORs adjusted for age and
ex are presented. Among Europeans, only one out of the 19
tudies (deCODE) demonstrated a nominally significant
ssociation between the KIF6 polymorphism and CAD but
n the opposite direction of the published literature (the
19Arg allele inversely associated with risk: log additive OR of
.93, 95% CI: 0.88 to 0.99, log dominant OR of 0.91, 95% CI:
.85 to 0.99). The meta-analysis produced a point estimate of
he log additive OR near unity with very tight confidence
ntervals (log additive OR of 0.98, 95% CI: 0.95 to 1.02, log
ominant OR of 0.97, 95% CI: 0.93 to 1.01). We also
ound no significant association between the KIF6 rs20455
NP and CAD among South Asian participants in the
NTERHEART study (log additive OR of 1.02, 95% CI:
.91 to 1.14, log dominant OR of 1.04, 95% CI: 0.87 to
.24), African American participants in the ADVANCE,
ATHGEN, and GeneSTAR studies (fixed-effects meta-
nalysis log additive OR of 0.91, 95% CI: 0.73 to 1.13, log
ominant OR of 0.81, 95% CI: 0.42 to 1.55), and a smaller
umber of Hispanic, East Asian, and admixed individuals
articipating in the ADVANCE study (see Table 2 for
etails).
Table 3 shows genotype counts and association analyses
estricted to the subgroup of case subjects with very early
nset disease (at younger than 50 years for men and at
ounger than 60 years for women) and controls within the
ame age range at the time of enrollment. Among this
ubgroup, we also observed no increase in the risk of CAD
n either the European carriers of the 719Arg allele com-
ared with noncarriers (fixed-effects meta-analysis log-
dditive OR: 0.99, 95% CI: 0.94 to 1.04; log-dominant OR:
.01, 95% CI: 0.95 to 1.08) or the non-European subjects
see Table 3 for details).
Last, our sensitivity analyses in Europeans restricting cases
o those defined on the basis of an MI in all 19 case-control
tudies also revealed no increased risk of CAD in European
arriers of the 719Arg allele compared with noncarriers, both
or the overall analysis (fixed-effects meta-analysis log-additive
R: 0.99, 95% CI: 0.96 to 1.03; log-dominant OR: 0.98, 95%
I: 0.94 to 1.02) and the subgroup analysis of early-onset MI dases (fixed-effects meta-analysis log-additive OR: 1.03, 95%
I: 0.98 to 1.09; log-dominant OR: 1.03, 95% CI: 0.97 to
.11). Additional details for these analyses are provided in
ables 2S and 3S in the Online Appendix.
None of the Q tests revealed heterogeneity in our meta-
nalyses (lowest p value  0.252), and all meta-analyses in
uropeans had an I2 value of 0%, suggesting that the variability
n effect sizes in Europeans was due entirely to sampling error
ithin the studies (see Table 4S in the Online Appendix).
hus, performing random-effects model meta-analyses was
ot necessary in Europeans because the results would be
dentical to the fixed-effects model. Only the log-dominant
odel for CAD overall among African Americans demon-
trated an I2 value 0%. For this stratum, the random-effects
odel (DerSimonian and Laird method) revealed an OR that
as similar to that of the fixed-effects model but with wider
Is (Table 4S in the Online Appendix).
iscussion
he principal finding of this study was the uniform lack of
levated risk of clinical CAD among carriers of the KIF6
19Arg allele compared with noncarriers in 19 case-control
tudies performed around the world. Our meta-analysis involv-
ng a very large number of subjects with European ancestry
17,000 cases and 39,369 controls) suggests that the risk of
AD among European carriers of the 719Arg allele is unlikely
o be increased by 2% compared with noncarriers.
Our study has 2 strengths in addition to the very high
ower conferred by studying a large number of European
ubjects. First, we studied a large number of early-onset
AD case subjects (men younger than 50 years of age and
omen younger than 60 years of age) but observed no
ssociation with KIF6 Trp719Arg and CAD despite the
xpectation that susceptibility alleles would be more preva-
ent in this subgroup (37). In this subgroup with early-onset
isease, we were able to rule out an increase in risk of 8%
n Europeans. Second, this is the only study to date that
xamines several non-European racial/ethnic groups. In
ach of the non-European case-control strata, we also found
o significant associations between the KIF6 Trp719Arg
olymorphism and CAD. However, the point estimates of the
Rs for these non-European subgroups have substantially
ider CIs than those derived in Europeans due to relatively
mall sample sizes (particularly in our Hispanic, East Asians,
dmixed Hispanic, and admixed non-Hispanics groups). Thus,
urther study of all these non-European race/ethnic groups is
eeded to rule out more modest effects on risk.
tudy limitations. Our study has 3 important limitations
elated to the case-control design. The first limitation is the
otential selection bias by studying only nonfatal cases of
AD. If the 719Arg allele increases the risk of incident fatal
AD more than the risk of incident nonfatal CAD, the
xclusion of incident fatal CAD cases could conceivably bias
he OR toward the null (i.e., OR: 1). However, the
ifference in relative risk between these 2 subgroups of cases
Kinesin-Like Protein-6 Trp719Arg Polymorphism (rs20455) Allele Frequencies, Genotype Counts,and Odds Ratios Adjusted for e and Sex in 19 Case-Contro Studies of CAD, Stratified by Race/Ethnic GroupTable 2 Kines Lik Pr tein-6 Trp719Arg Polymorphism (rs20455) Allele Frequencies, Genotype Counts,and Odds Ratios Adjusted for Age and Sex in 19 Case-Control Studies of CAD, Stratified by Race/Ethnic Group
Cases (CAD) Controls OR (95% CI) and p Values
n
Allele Freq
719Arg
719Trp/
719Trp
719Arg/
719Trp
719Arg/
719Arg n
Allele Freq
719Arg
719Trp/
719Trp
719Arg/
719Trp
719Arg/
719Arg
Log-Additive Mode
of Inheritance p Value
Log-Dominant Mode
of Inheritance p Value
Europeans
ADVANCE 275 0.345 119 122 34 311 0.378 122 143 46 0.87 (0.69–1.10) 0.249 0.84 (0.60–1.16) 0.289
AMI Gene 793 0.369 311 379 103 1,121 0.381 430 528 163 0.89 (0.75–1.04) 0.142 0.90 (0.71–1.13) 0.349
CATHGEN 1,298 0.361 545 570 183 730 0.355 297 347 86 1.02 (0.89–1.18) 0.749 0.96 (0.79–1.17) 0.674
deCODE* 4,313 0.300 2,131 1,779 403 24,952 0.312 11,813 10,689 2,450 0.93 (0.88–0.99) 0.018 0.91 (0.85–0.99) 0.020
FINRISK 167 0.374 64 81 22 172 0.355 73 76 23 1.09 (0.80–1.49) 0.596 1.18 (0.76–1.82) 0.458
GeneSTAR 285 0.368 106 148 31 1,579 0.365 626 752 201 0.99 (0.82–1.21) 0.939 1.09 (0.83–1.43) 0.543
GerMIFS I† 722 0.367 293 328 101 1,643 0.368 662 753 228 0.97 (0.84–1.13) 0.742 0.97 (0.88–1.08) 0.661
GerMIFS II 1,126 0.367 447 529 150 1,277 0.359 522 593 162 1.01 (0.89–1.14) 0.893 0.99 (0.91–1.08) 0.770
HARPS 505 0.404 187 228 90 559 0.381 216 260 83 1.10 (0.92–1.31) 0.279 1.07 (0.83–1.37) 0.602
INTERHEART 789 0.362 335 337 117 859 0.354 354 402 103 1.03 (0.90–1.19) 0.671 0.95 (0.78–1.15) 0.573
IFS*‡ 482 0.344 203 226 53 622 0.346 261 292 69 1.03 (0.81–1.30) 0.835 — —
MDC 86 0.372 35 38 13 99 0.394 33 54 12 0.91 (0.60–1.39) 0.667 0.73 (0.40–1.33) 0.305
MedStar 875 0.349 370 399 106 447 0.364 174 221 52 0.99 (0.80–1.22) 0.919 0.91 (0.68–1.22) 0.527
MGH PCAD 204 0.353 89 86 29 260 0.348 114 111 35 1.04 (0.82–1.31) 0.878 1.03 (0.69–1.52) 0.904
MAHI 807 0.367 322 377 108 637 0.359 256 304 77 1.04 (0.89–1.21) 0.647 1.01 (0.82–1.25) 0.919
PennCATH 933 0.379 359 441 133 468 0.358 194 213 61 1.04 (0.86–1.26) 0.666 1.03 (0.79–1.33) 0.850
REGICOR 312 0.348 134 139 39 317 0.339 141 137 39 1.02 (0.78–1.34) 0.747 1.06 (0.77–1.45) 0.716
VHS 1,106 0.378 437 501 168 383 0.372 145 191 47 1.03 (0.87–1.22) 0.757 0.93 (0.73–1.19) 0.568
WTCCC CAD 1,922 0.356 792 890 240 2,933 0.355 1,242 1,299 392 1.02 (0.93–1.12) 0.624 1.09 (0.96–1.24) 0.189
Total meta-analysis 17,000 39,369 0.98 (0.95–1.02) 0.349 0.97 (0.93–1.01) 0.137
Non-Europeans
ADVANCE admixed Hispanic 34 0.412 12 16 6 22 0.455 7 10 5 0.77 (0.34–1.67) 0.507 0.73 (0.21–2.36) 0.607
ADVANCE admixed non-
Hispanic
74 0.419 27 32 15 37 0.622 10 8 19 0.83 (0.44–1.57) 0.555 1.44 (0.49–4.41) 0.506
ADVANCE African Americans 49 0.745 4 17 28 87 0.816 5 22 60 0.70 (0.39–1.23) 0.207 0.70 (0.18–3.00) 0.619
ADVANCE East Asians 45 0.356 19 20 6 35 0.486 9 18 8 0.60 (0.30–1.13) 0.114 0.48 (0.18–1.25) 0.135
ADVANCE Hispanic 28 0.375 11 13 4 22 0.364 8 12 2 1.07 (0.45–2.58) 0.876 0.88 (0.27–2.82) 0.831
CathGEN African Americans 277 0.762 16 100 161 240 0.783 9 86 145 0.89 (0.66–1.21) 0.465 0.58 (0.25–1.37) 0.213
GeneSTAR African
Americans
93 0.796 2 34 57 1,073 0.786 53 353 667 1.05 (0.72–1.51) 0.813 2.35 (0.56–9.83) 0.241
INTERHEART (South Asians) 1,092 0.451 351 498 243 1,187 0.449 389 531 267 1.02 (0.91–1.14) 0.791 1.04 (0.87–1.24) 0.669
African Americans total meta-
analysis
419 1,400 0.91 (0.73–1.13) 0.380 0.81 (0.42–1.55) 0.520
*Adjusted for relatedness. †p Values adjusted by genomic control method as   1.27 ‡Approach to analysis unable to produce dominant model odds ratios (OR).
CI  confidence interval; other abbreviations as in Table 1.
1560
Assim
es
etal.
JACC
Vol.56,No.19,2010
Kinesin-Like
Protein-6
and
Coronary
Disease
Novem
ber2,2010:1552–63
Kinesin-Like Protein-6 Trp719Arg Polymorphism (rs20455) Allele Frequencies, Genotype Counts, and Odds Ratios Adjustedfor Age and Sex in 19 Case-Control Studies of CAD, Stratified by Race/Ethnic roup and Restricted to Early-Onset Disease(Ag at Onset f CAD Younger Than 50 Y ar of Age for M n and Younger Than 60 Years f Age for Women) and Similarly Aged Controls
Table 3
Kinesin-Like Protein-6 Trp719Arg Polymorphism (rs20455) Allele Frequencies, Genotype Counts, and Odds Ratios Adjusted
for Age and Sex in 19 Case-Control Studies of CAD, Stratified by Race/Ethnic Group and Restricted to Early-Onset Disease
(Age at Onset of CAD Younger Than 50 Years of Age for Men and Younger Than 60 Years of Age for Women) and Similarly Aged Controls
Cases (CAD) Controls OR (95% CI) and p Values
n
Allele Freq
719Arg
719Trp/
719Trp
719Arg/
719Trp
719Arg/
719Arg n
Allele Freq
719Arg
719Trp/
719Trp
719Arg/
719Trp
719Arg/
719Arg
Log-Additive Mode
of Inheritance p Value
Log-Dominant Mode
of Inheritance p Value
Europeans
ADVANCE 275 0.345 119 122 34 311 0.378 122 143 46 0.87 (0.69–1.10) 0.249 0.84 (0.60–1.16) 0.289
AMI Gene 296 0.380 117 133 46 193 0.415 68 90 35 0.98 (0.74–1.30) 0.875 1.02 (0.67–1.54) 0.929
CATHGEN 585 0.366 233 276 76 295 0.359 121 136 38 0.99 (0.78–1.28) 0.990 0.98 (0.70–1.37) 0.900
deCODE* 750 0.292 375 312 63 12,548 0.312 5,955 5,366 1,227 0.91 (0.72–1.16) 0.450 0.95 (0.69–1.29) 0.730
FINRISK 167 0.374 64 81 22 172 0.355 73 76 23 1.09 (0.80–1.49) 0.596 1.18 (0.76–1.82) 0.458
GeneSTAR 201 0.358 79 100 22 1,579 0.365 626 752 201 0.95 (0.76–1.18) 0.627 0.99 (0.73–1.35) 0.951
GerMIFS I† 412 0.367 168 186 58 387 0.377 152 178 57 0.99 (0.80–1.23) 0.949 0.99 (0.87–1.16) 0.999
GerMIFS II 524 0.365 210 245 69 709 0.363 286 331 92 0.97 (0.81–1.16) 0.760 0.97 (0.86–1.10) 0.611
HARPS 505 0.404 187 228 90 559 0.381 216 260 83 1.10 (0.92–1.31) 0.279 1.07 (0.83–1.37) 0.602
INTERHEART 195 0.364 85 78 32 216 0.343 92 90 24 1.09 (0.82–1.44) 0.559 0.96 (0.65–1.42) 0.837
IFS*‡ 371 0.342 154 180 37 309 0.353 129 142 38 0.86 (0.63–1.16) 0.315
MDC 86 0.372 35 38 13 99 0.394 33 54 12 0.91 (0.60–1.39) 0.667 0.73 (0.40–1.33) 0.305
MedStar 601 0.351 255 270 76 151 0.358 61 72 18 0.98 (0.74–1.29) 0.878 0.91 (0.62–1.33) 0.612
MGH PCAD 204 0.353 89 86 29 260 0.348 114 111 35 1.04 (0.82–1.31) 0.878 1.03 (0.69–1.52) 0.904
MAHI 227 0.392 81 114 32 190 0.363 77 88 25 1.14 (0.85–1.51) 0.386 1.12 (0.80–1.79) 0.374
PennCATH 354 0.383 134 169 51 128 0.359 53 58 17 1.11 (0.82–1.49) 0.508 1.16 (0.73–1.83) 0.539
REGICOR 312 0.348 134 139 39 317 0.339 141 137 39 1.02 (0.78–1.34) 0.747 1.06 (0.77–1.45) 0.716
VHS 197 0.409 71 91 35 113 0.420 33 65 15 0.88 (0.56–1.38) 0.570 0.72 (0.38–1.37) 0.320
WTCCC CAD 1,085 0.359 444 503 138 2,612 0.355 1101 1167 344 1.04 (0.94–1.16) 0.444 1.10 (0.95–1.27 0.216
Total meta-analysis 7,347 21,148 0.99 (0.94–1.04) 0.729 1.01 (0.95–1.08) 0.831
Non-Europeans
ADVANCE admixed Hispanic 34 0.412 12 16 6 22 0.455 7 10 5 0.77 (0.34–1.67) 0.507 0.73 (0.21–2.36) 0.607
ADVANCE admixed non-
Hispanic
74 0.419 27 32 15 37 0.622 10 8 19 0.83 (0.44–1.57) 0.555 1.44 (0.49–4.41) 0.506
ADVANCE African Americans 49 0.745 4 17 28 87 0.816 5 22 60 0.70 (0.39–1.23) 0.207 0.70 (0.18–3.00) 0.619
ADVANCE East Asians 45 0.356 19 20 6 35 0.486 9 18 8 0.60 (0.30–1.13) 0.114 0.48 (0.18–1.25) 0.135
ADVANCE Hispanic 28 0.375 11 13 4 22 0.364 8 12 2 1.07 (0.45–2.58) 0.876 0.88 (0.27–2.82) 0.831
CathGEN African Americans 157 0.755 7 63 87 128 0.781 5 46 77 1.02 (0.64–1.61) 0.950 0.89 (0.23–3.46) 0.860
GeneSTAR African
Americans
70 0.807 2 23 45 1,073 0.786 53 353 667 1.15 (0.75–1.76) 0.532 1.79 (0.43–7.50) 0.427
INTERHEART South Asians 515 0.458 163 232 120 633 0.453 203 286 144 1.03 (0.88–1.21) 0.701 1.04 (0.81–1.34) 0.735
African Americans total meta-
analysis
276 1,288 1.06 (0.76–1.49) 0.721 1.05 (0.87–1.26) 0.609
Controls are restricted to men younger than 50 years of age and women younger than 60 years of age at the time of blood draw to match the sex-specific age range of cases. *Adjusted for relatedness. †p Values adjusted by genomic control method as  1.27. ‡Approach
to analysis unable to produce dominant model OR.
Abbreviations as in Tables 1 and 2.
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iased OR in our study, given that the majority of incident
AD events are not fatal, especially among subjects with
arly-onset disease (e.g., in the ARIC surveillance study,
0% to 35% of subjects age 60 years or older and 10% to
0% of subjects younger than the age of 60 years died as a
onsequence of a complication of their initial presentation
f CAD [38]). The second potential limitation is our
nability to measure traditional risk factors as robustly as
hey are measured in prospective studies. We therefore
ade no attempt to fully adjust ORs for all traditional risk
actors of CAD. However, prospective studies published to
ate suggest that traditional risk factors are not correlated
ith the KIF6 Trp719Arg polymorphism, making adjust-
ent unnecessary (1–5). Last, our study did not allow us to
xplore whether statin use modifies the effect of the 719Arg
llele on risk as was done in the WOSCOPS, CARE, and
ROVE IT–TIMI 22 trials because reliable information on
he use of statins in relation to the incident event was not
vailable for most studies. However, we believe it unlikely
hat our null results are a consequence of a high prevalence
f the use of statins at the time of the event in cases. In fact,
e suspect that the overall prevalence of the use of statins in
ur set of 19 case-control studies is actually lower than the
revalence of use observed at the last follow-up for partic-
pants in the ARIC, CHS, and WHS studies (39–41)
ecause a majority of our case-control studies restricted their
ecruitment and/or genotyping efforts to very early onset
ases and young controls. For example, in the ADVANCE
tudy, which focused on very early onset CAD (men
ounger than 45 years of age, women younger than 55 years
f age), access to the electronic pharmacy records confirmed
hat only a small proportion of cases (14.4%) and controls
4.7%) were taking statins during the appropriate time
indow of exposure.
Is it possible that other less obvious sources of bias are
esponsible for the differences in associations observed
etween case-control and cohort studies of KIF6? Although
e cannot rule out this possibility, we also deem this
cenario unlikely, given that such cryptic biases, if they exist,
ave not influenced associations between SNPs at the
p21.3 locus and CAD in the same manner (9,10). In fact,
any of the case-control studies included in this report have
roduced ORs of disease for the 9p21.3 locus equivalent to
r larger than the HRs derived from cohort studies
9,10,12,14,42–44). These cohort studies include the 2
argest cohort studies to date reporting on the association
etween KIF6 and CAD (ARIC and WHS). Thus, we are
eft with the real possibility that the initial reports falsely
uggested an association between variation in KIF6 and
AD. The reasons for this are unclear but include the
ossibility of chance findings or inadequate correction for
ultiple testing (45–47). The lack of biological studies
mplicating KIF6 in the pathogenesis of coronary atheroscle-
osis combined with the lack of consistent evidence of expres-
ion of this gene in relevant tissues such as the vasculature48,49) could also argue for a false-positive association. How-
ver, many recent population genetic studies of complex traits
ave clearly demonstrated that such mechanistic data are not
ecessary to validate highly significant associations uncovered
hrough the genome-wide association approach to discovery
50).
Our findings question not only the usefulness of the KIF6
est in identifying subjects at increased risk of incident or
ecurrent CAD but also its usefulness in identifying subjects
ost likely to benefit from statins. Although we could not
est the latter hypothesis directly, the previously reported
nteraction between genotype and benefit from statins is
argely dependent on the validity of the association among
ubjects not taking statins, which could not be replicated in
his study. We also call attention to the fact that the
nteraction term p value between genotype and statin use
as only marginally significant in the WOSCOPS (p 0.021)
nd PROVEIT–TIMI 22 (p  0.018) trials and not signifi-
ant in the CARE trial (adjusted p 0.39) (2,3). Despite these
bservations, additional high-quality prospective cohort studies
f the effect of the KIF6 variant on CAD risk among users and
onusers of statins are needed before any firm conclusions can
e made on the validity of this interaction.
onclusions
e were unable to confirm an increased risk of CAD in
arriers of the KIF6 719Arg allele compared with noncar-
iers in a very large number of European subjects. We also
bserved no compelling evidence of an association between
he KIF6 Trp719Arg SNP and CAD in multiple other
ace/ethnic groups and among subjects with early-onset
AD. Our null results are unlikely to be a consequence of
election bias, a high prevalence of use of statins among
ases, or other cryptic biases. These findings do not support
he clinical utility of testing for the KIF6 Trp719Arg
olymorphism to identify subjects at higher risk of CAD
nd indirectly question whether genotype information at
his locus can reliably identify a population of subjects most
ikely to benefit from the use of statins.
eprint requests and correspondence: Dr. Themistocles L.
ssimes, Population Health Sciences Building, Stanford Univer-
ity School of Medicine, Stanford, California 94304-1334. E-mail:
assimes@stanford.edu.
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